Join
Live feed
·
INSIDERFilingvia Quantisnow
Akero Therapeutics Inc. logo

Chief Development Officer Yale Catriona returned 74,800 shares to the company, closing all direct ownership in the company (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
AKRO· Akero Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKRO (Akero Therapeutics Inc.) and more on Quantisnow.